Browse treatments

…tron is administered intravenously as a stat dose on day one of chemotherapy. Palonosetron has a 40 hour half-life,2 thus it is advised that…

…io)), quality of life advantages of talazoparib (Talzenna) over chemotherapy, and functional benefits of trastuzumab deruxtecan (Enhertu).A …

…ophysin expression. Despite timely whole-brain radiotherapy and chemotherapy, his condition deteriorated rapidly, and he succumbed within we…

…received surgery (123 women, 55.7% vs 107 men, 38.6%, p<0.001), chemotherapy (149 women, 67.4% vs 153 men, 55.2%, p=0.0057), biological ther…

… Significant pain reduction was reported in patients undergoing chemotherapy at days 1 (p=0.005) and 5 (p=0.004) post-treatment. Sleep quali…

…8Ga]Ga-PDL1p uptake, [18F]FDG uptake, and PD-L1 expression with immunotherapy response were analyzed, along with their predictive values for …

…nal liver metastases. Remission was obtained with radiotherapy, chemotherapy, bone resorptive inhibitors, mitotane and repeat radiofrequency…

… As for systemic therapy, intravenous bevacizumab combined with chemotherapy has demonstrated clinical benefits in NSCLC patients. However, …

…estive (24%), and breast (12%) cancer. Treatments received were chemotherapy (70.2%), immunotherapy (22.2%), and targeted therapies (11.4%);…

…high risk patient subgroups by analysing the combined impact of chemotherapy delivery and clinical status.Aim and Objectives The main object…

…h dual HER2 blockade, combining Trastuzumab and Pertuzumab with chemotherapy, is currently the therapeutic option in the neoadjuvant setting…

…t affected age group was 60–79 years (62%). Main therapies were chemotherapy (38%), immunotherapy (31%), biological therapy (21%), and other…